Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL276016 | 0.78 | TLR4 (0.51) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL2470785 | 0.78 | TLR4 (0.51) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL28368812 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL3656801 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL7697030 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL7733726 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL929873 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL10792572 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL7392059 | 0.77 | TLR4 (0.50) | MAPK1MCL1CYP2D6KDM4EHSD17B10 | |
| SCHEMBL20303983 | 0.75 | MAPK1 (0.54) | MAPK1MCL1CYP2D6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| EP-2621544-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE Healthcare UK Limited (GB) | 2013-08-07 | — | — | EP | disclosed |
| EP-2618850-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE Healthcare UK Limited (GB) | 2013-07-31 | — | — | EP | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012041953-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012038532-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | MAPK1 4786/4885MCL1 1004/4885CYP2D6 1258/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | MAPK1 4123/4885MCL1 124/4885CYP2D6 2778/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | MAPK1 4786/4885MCL1 1004/4885CYP2D6 1258/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | MAPK1 4431/4885MCL1 1805/4885CYP2D6 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.